BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 10433010)

  • 1. Fibrogenesis serum markers in patients with chronic hepatitis C treated with alpha-IFN.
    Fabris P; Marranconi F; Bozzola L; Biasin MR; De Lazzari F; Plebani M; Benedetti P; Tositti G; Pellizzer G; Stecca C; de Lalla F
    J Gastroenterol; 1999 Jun; 34(3):345-50. PubMed ID: 10433010
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Liver stellate cells and aminoterminal peptide of type III procollagen in chronic hepatitis C treated with interferon.
    Gabrielli GB; Casaril M; Stanzial AM; Colombari R; Pasino M; Corrocher R
    Hepatogastroenterology; 2003; 50(54):2017-21. PubMed ID: 14696456
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Alpha-interferon improves liver fibrosis in chronic hepatitis C: clinical significance of the serum N-terminal propeptide of procollagen type III.
    Serejo F; Costa A; Oliveira AG; Ramalho F; Batista A; De Moura MC
    Dig Dis Sci; 2001 Aug; 46(8):1684-9. PubMed ID: 11508668
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Changes in serum tissue inhibitor of matrix metalloproteinase-1 after interferon alpha treatment in chronic hepatitis C.
    Mitsuda A; Suou T; Ikuta Y; Kawasaki H
    J Hepatol; 2000 Apr; 32(4):666-72. PubMed ID: 10782917
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Changes in histological lesions and serum fibrogenesis markers in chronic hepatitis C patients non-responders to interferon alpha.
    Leroy V; De Traversay C; Barnoud R; Hartmann JD; Baud M; Ouzan D; Zarski JP
    J Hepatol; 2001 Jul; 35(1):120-6. PubMed ID: 11495029
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Changes of liver fibrosis in chronic hepatitis C patients with no response to interferon-alpha therapy: including quantitative assessment by a morphometric method.
    Yagura M; Murai S; Kojima H; Tokita H; Kamitsukasa H; Harada H
    J Gastroenterol; 2000; 35(2):105-11. PubMed ID: 10680665
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Longitudinal evaluation of a fibrosis index combining MMP-1 and PIIINP compared with MMP-9, TIMP-1 and hyaluronic acid in patients with chronic hepatitis C treated by interferon-alpha and ribavirin.
    Trocme C; Leroy V; Sturm N; Hilleret MN; Bottari S; Morel F; Zarski JP
    J Viral Hepat; 2006 Oct; 13(10):643-51. PubMed ID: 16970595
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Serum procollagen type III peptide in chronic hepatitis B. Relationship to disease activity and response to interferon-alpha therapy.
    Giustina G; Fattovich G; De Paoli M; Guido M; Favarato S; Rugge M; Alberti A; Ruol A; Plebani M
    Int J Clin Lab Res; 1996; 26(1):33-6. PubMed ID: 8739853
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Serum variations of 2 markers of fibrogenesis in chronic hepatitis C treated with alpha interferon].
    Soresi M; Bascone F; Agate V; Carroccio A; Barresi E; Cartabellotta A; Aragona F; Montalto G
    Recenti Prog Med; 1997 Feb; 88(2):73-6. PubMed ID: 9148370
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical significance of serum hyaluronic acid as a fibrosis marker in chronic hepatitis C patients treated with interferon-alpha: histological evaluation by a modified histological activity index scoring system.
    Ninomiya T; Yoon S; Hayashi Y; Sugano M; Kumon Y; Seo Y; Shimizu K; Kasuga M
    J Gastroenterol Hepatol; 1998 Jan; 13(1):68-74. PubMed ID: 9737575
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Serum markers of hepatic fibrogenesis in chronic hepatitis type C treated with alfa-2A interferon.
    Gallorini A; Plebani M; Pontisso P; Chemello L; Masiero M; Mantovani G; Alberti A
    Liver; 1994 Oct; 14(5):257-64. PubMed ID: 7997085
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term variations of serum laminin and procollagen III peptide in chronic HCV hepatitis after alpha-interferon therapy.
    Casaril M; Capra F; Gabrielli GB; Tognella P; Rizzi A; Squarzoni S; De Maria E; Colombari R; De Sandre G; Corrocher R
    Ital J Gastroenterol; 1996 Jan; 28(1):15-9. PubMed ID: 8743068
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of antiviral therapy on markers of fibrogenesis in patients with chronic hepatitis C.
    Nøjgaard C; Johansen JS; Krarup HB; Holten-Andersen M; Møller A; Bendtsen F;
    Scand J Gastroenterol; 2003 Jun; 38(6):659-65. PubMed ID: 12825876
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Serum laminin and type III procollagen in chronic hepatitis C. Diagnostic value in the assessment of disease activity and fibrosis.
    Gabrielli GB; Capra F; Casaril M; Squarzoni S; Tognella P; Dagradi R; De Maria E; Colombari R; Corrocher R; De Sandre G
    Clin Chim Acta; 1997 Sep; 265(1):21-31. PubMed ID: 9352126
    [TBL] [Abstract][Full Text] [Related]  

  • 15. alpha-Interferon in the treatment of chronic viral hepatitis: effects on fibrogenesis serum markers.
    Capra F; Casaril M; Gabrielli GB; Tognella P; Rizzi A; Dolci L; Colombari R; Mezzelani P; Corrocher R; De Sandre G
    J Hepatol; 1993 Apr; 18(1):112-8. PubMed ID: 8340603
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antifibrogenic activity of interferon alpha in chronic hepatitis C.
    Suou T
    J Gastroenterol; 1999 Jun; 34(3):426-7. PubMed ID: 10433027
    [No Abstract]   [Full Text] [Related]  

  • 17. Decrease in serum levels of markers of hepatic connective tissue turnover during and after treatment of chronic hepatitis B with interferon-alpha.
    Teran JC; Mullen KD; Hoofnagle JH; McCullough AJ
    Hepatology; 1994 Apr; 19(4):849-56. PubMed ID: 8138256
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Resistance to alpha interferon therapy in HCV chronic liver disease: role of hepatic fibrosis.
    Di Costanzo GG; Ascione A; Lanza AG; De Luca M; Bracco A; Lojodice D; Marsilia GM; Ferbo U
    Ital J Gastroenterol; 1996 Apr; 28(3):140-6. PubMed ID: 8789824
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Matrix-derived serum markers in monitoring liver fibrosis in children with chronic hepatitis B treated with interferon alpha.
    Lebensztejn DM; Sobaniec-Lotowska ME; Kaczmarski M; Voelker M; Schuppan D
    World J Gastroenterol; 2006 Jun; 12(21):3338-43. PubMed ID: 16733849
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Oxidative stress in chronic hepatitis C: the effect of interferon therapy and correlation with pathological features.
    Serejo F; Emerit I; Filipe PM; Fernandes AC; Costa MA; Freitas JP; de Moura MC
    Can J Gastroenterol; 2003 Nov; 17(11):644-50. PubMed ID: 14631465
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.